|
HIV
Coinfection with Hepatitis B or Hepatitis C 
HIV-HCV
Coinfected Patients Develop Liver Cancer at a Younger Age than HCV-monoinfected
patients but There Is No Difference in Survival Times between the
Two Groups - 8/26/05
Higher
Non Nucleoside and Lower Lopinavir Levels in HIV-HCV Coinfected
Patients - 8/10/05
Safety of a Fosamprenavir/Ritonavir-containing
Regimen Over 120 Weeks in HIV Positive Treatment-naïve Adults with
or without hepatitis B and/or C Coinfection
-
8/01/05
Safety
of Abacavir + Lamivudine-based HAART in ART-naïve HIV Positive Subjects
with and without Hepatitis B and/or Hepatitis C Coinfection
-
8/01/05
Pattern
of Hepatotoxicity on Different Antiretroviral Regimens in HIV Patients
with or without Chronic Hepatitis B or Hepatitis C
-
8/01/05
Liver
Disease and Not HCV Coinfection May Be Predictive of a Higher Discontinuation
of HAART
-
8/01/05
Experimental Antiretrovirals / New Antiretrovirals
Experimental
NNRTI TMC 120 Appears Safe and Effective as Microbicide - 8/10/05
Antiviral
Activity and Safety of GW695634, a Next Generation NNRTI, in Patients
with NNRTI-resistant HIV -
8/08/05
Salvage
Study of Experimental HIV Protease Inhibitor TMC-114 from Tibotec
Yields Outstanding Results
-
8/01/05
GlaxoSmithKline
Begins Phase III Trials of CCR5 Antagonist Aplaviroc - 7/29/05
Dosing
Study of SCH 417690, New CCR5 Receptor Antagonist from Schering-Plough
-
7/27/05
New
Nucleoside Analog Reverset (D-d4FC) Shows Promise in Phase II Study
of Treatment-experienced Patients -
7/27/05
Phase 1/2a Safety and Efficacy Data
of CCR5 Antagonist Maraviroc (UK-427,857) -
7/27/05
Protease Inhibitors (PIs) and Boosted PIs
Establishing
the Clinical Cutoffs for Atazanavir and Tipranavir - 9/10/05
HIV
Protease Inhibitors Have Anti-malarial Effects - 8/22/05
Improvements
in Lopinavir/Ritonavir Formulation - 8/10/05
Higher Non Nucleoside and Lower Lopinavir Levels in HIV-HCV Coinfected
Patients - 8/10/05
Adverse
Events are the Main Cause of Treatment Failure in a Multicentre
Trial in Naïve Patients, comparing Zidovudine/Lamivudine vs Stavudine/Didanosine,
plus Efavirenz, Nevirapine or Indinavir/Ritonavir - 8/08/05
2-year
Follow-Up of Combination Lopinavir/Ritonavir-Efavirenz - 8/08/05
Tipranavir/ritonavir
Demonstrates Superior Response to Lopinavir/ritonavir, Amprenavir/ritonavir
or Saquinavir/ritonavir in PI-experienced Patients - 8/08/05
Tipranavir/ritonavir
500 mg/200 mg BID Drives Week 24 viral load <400 copies/mL When
Combined with Enfuvirtide in Protease Inhibitor-experienced HIV
Patients - 8/03/05
Once-Daily
Salvage Regimens for Heavily Treatment-experienced HIV-Infected
Patients in the Atazanavir Early Access Program in Spain - 8/03/05
Safety of a Fosamprenavir/Ritonavir-containing
Regimen Over 120 Weeks in HIV Positive Treatment-naïve Adults with
or without hepatitis B and/or C Coinfection
-
8/01/05
Treatment-naïve
Patients Treated with Ritonavir-boosted Saquinavir Show No Significant
Resistance to Protease Inhibitors - 7/29/05
Switching
to Atazanavir from Other PI-based HAART Maintains Suppression, Results
in Fewer Viral Rebounds and Improves Lipids and GI Tolerance: The
SWAN Study - 7/29/05
Once-daily
versus Twice-daily Lopinavir/Ritonavir in Treatment-naïve Patients:
96-week Results - 7/29/05
Immunologic
Reconstitution through 6 Years in Antiretroviral-Naïve Patients
Treated with Lopinavir/Ritonavir - 7/29/05
Non Nucleoside Reverse Transcriptase Inhibitors
(NNRTIs)
Preventing
Mother-to-Child Transmission (MTCT) and Nevirapine Resistance
- 9/08/05
Experimental
NNRTI TMC 120 Appears Safe and Effective as Microbicide - 8/10/05
Higher
Non Nucleoside and Lower Lopinavir Levels in HIV-HCV Coinfected
Patients - 8/10/05
High
Rate of Virological Failure during Once-daily Therapy with Tenofovir
+ Didanosine 250mg + Efavirenz in Treatment-naive Patients - 8/08/05
Adverse
Events are the Main Cause of Treatment Failure in a Multicentre
Trial in Naïve Patients, comparing Zidovudine/Lamivudine vs Stavudine/Didanosine,
plus Efavirenz, Nevirapine or Indinavir/Ritonavir - 8/08/05
Tenofovir
in Combination with Lamivudine and Efavirenz in Treatment-naïve
HIV Patients -- 8/08/05
2-year
Follow-Up of Combination Lopinavir/Ritonavir-Efavirenz - 8/08/05
Tipranavir/ritonavir
Demonstrates Superior Response to Lopinavir/ritonavir, Amprenavir/ritonavir
or Saquinavir/ritonavir in PI-experienced Patients - 8/08/05
Efficacy
and Safety of Once-Daily Abacavir/Lamivudine Fixed-dose Combination
+ Efavirenz - 8/03/05
Nevirapine
Concentration in Cervico-vaginal and Oropharyngeal Secretions
- 8/03/05
Timing
of Maternal and Infant Nevirapine and the Risk of Mother-to-child
Transmission of HIV - 8/03/05
6-month
Immunological Response with HAART-containing Nevirapine in HIV Positive
Women Post-exposure to Single-dose of Nevirapine for PMTCT - 8/03/05
Switch
from PI- to Sustiva-based HAART Shows No Impact of Race on Efficacy
and Nervous System Symptoms - 8/03/05
Nucleoside/tide Reverse Transcriptase Inhibitors
A
New Mechanisms for NRTI Resistance: Mutations the RNase H Encoding
Region - 9/08/05
Absence
of K65R in Subjects Failing Tenofovir in GS934 - 9/08/05
The
Effect of the M184V Mutation on HIV Replication and the Maintenance
of CD4+ Counts - 9/08/05
Adverse
Events are the Main Cause of Treatment Failure in a Multicentre
Trial in Naïve Patients, comparing Zidovudine/Lamivudine vs Stavudine/Didanosine,
plus Efavirenz, Nevirapine or Indinavir/Ritonavir - 8/08/05
Tenofovir
in Combination with Lamivudine and Efavirenz in Treatment-naïve
HIV Patients -- 8/08/05
Lack
of Resistance to Tenofovir at Week 48 and Impact of Baseline Resistance
Mutations on Treatment Response - 8/08/05
Efficacy
and Safety of a Once-daily Fixed-dose Combination of Abacavir/Lamivudine
versus Abacavir Twice-daily and Lamivudine Once-daily as Separate
Entities in Treatment-experienced Patients -- 8/08/05
Quadruple
Nucleoside/tide Regimen of Trizivir + Tenofovir Is Effective Following
Early Virologic Failure on an Initial Regimen Containing a Thymidine
Analog + Lamivudine + a PI or NNRTI - 8/08/05
Patient
Satisfaction with Abacavir-Lamivudine Fixed-dose Combination (FDC)
Tablet Once daily (QD) Compared with Abacavirand Lamivudine Twice-daily
- 8/08/05
Switching
from Stavudine to Tenofovir Decreases Cardiovascular Risk - 8/05/05
Tenofovir
Affects Renal Function but Renal Failure Is Rare - 8/03/05
Efficacy
and Safety of Once-Daily Abacavir/Lamivudine Fixed-dose Combination
+ Efavirenz - 8/03/05
Routine
Use of Combined Zidovudine and Nevirapine Regimen in MTCT-Plus Program
- 8/03/05
Entry Inhibitors
Salvage
Therapy in Different Clinical Settings - 8/05/05
Tipranavir/ritonavir
500 mg/200 mg BID Drives Week 24 viral load <400 copies/mL When
Combined with Enfuvirtide in Protease Inhibitor-experienced HIV
Patients - 8/03/05
Therapy for Treatment-naïve Individuals
Adverse
Events are the Main Cause of Treatment Failure in a Multicentre
Trial in Naïve Patients, comparing Zidovudine/Lamivudine vs Stavudine/Didanosine,
plus Efavirenz, Nevirapine or Indinavir/Ritonavir - 8/08/05
2-year
Follow-Up of Combination Lopinavir/Ritonavir-Efavirenz - 8/08/05
Lack
of Resistance to Tenofovir at Week 48 and Impact of Baseline Resistance
Mutations on Treatment Response - 8/08/05
High
Rate of Virological Failure during Once-daily Therapy with Tenofovir
+ Didanosine 250mg + Efavirenz in Treatment-naive Patients - 8/08/05
Efficacy
and Safety of Once-Daily Abacavir/Lamivudine Fixed-dose Combination
+ Efavirenz - 8/03/05
Immunologic
Status at Time of Initial Evaluation: Consequences of Delayed HIV
Diagnoses
-
8/01/05
Evaluation
of 3 Once-daily Regimens as First-line HAART
-
8/01/05
Outcome
of Once-daily Regimen with Didanosine, Lamivudine and Efavirenz
in Treatment-naïve Patients
-
8/01/05
Superior
48-week Outcome for Tenofovir, Emtricitabine and Efavirenz Combination
Regimen Compared to Fixed-dose Zidovudine/Lamivudine and Efavirenz
in Treatment-naïve Patients - 7/29/05
Treatment-naïve
Patients Treated with Ritonavir-boosted Saquinavir Show No Significant
Resistance to Protease Inhibitors - 7/29/05
Once-daily
versus Twice-daily Lopinavir/Ritonavir in Treatment-naïve Patients:
96-week Results - 7/29/05
Immunologic
Reconstitution through 6 Years in Antiretroviral-Naïve Patients
Treated with Lopinavir/Ritonavir - 7/29/05
Therapy
for Treatment-experienced Individuals
Efficacy
and Safety of a Once-daily Fixed-dose Combination of Abacavir/Lamivudine
versus Abacavir Twice-daily and Lamivudine Once-daily as Separate
Entities in Treatment-experienced Patients -- 8/08/05
2-year
Follow-Up of Combination Lopinavir/Ritonavir-Efavirenz - 8/08/05
Tipranavir/ritonavir
500 mg/200 mg BID Drives Week 24 viral load <400 copies/mL When
Combined with Enfuvirtide in Protease Inhibitor-experienced HIV
Patients - 8/03/05
Once-Daily
Salvage Regimens for Heavily Treatment-experienced HIV-Infected
Patients in the Atazanavir Early Access Program in Spain - 8/03/05
Salvage
Study of Experimental HIV Protease Inhibitor TMC-114 from Tibotec
Yields Outstanding Results
-
8/01/05
Switching
to Atazanavir from Other PI-based HAART Maintains Suppression, Results
in Fewer Viral Rebounds and Improves Lipids and GI Tolerance: The
SWAN Study - 7/29/05
Lipids and Metabolic Complications
Metabolic and Morphological
Disturbances Reported at the 3rd IAS Conference - 8/22/05
Switching
to Atazanavir from Other PI-based HAART Maintains Suppression, Results
in Fewer Viral Rebounds and Improves Lipids and GI Tolerance: The
SWAN Study - 7/29/05
Prevention of HIV Infection
Experimental
NNRTI TMC 120 Appears Safe and Effective as Microbicide - 8/10/05
Pharmacokinetics and Drug Interactions
Improvements
in Lopinavir/Ritonavir Formulation - 8/10/05
Complications of Therapy / Adverse Events
/ Side Effects
Adverse
Events are the Main Cause of Treatment Failure in a Multicentre
Trial in Naïve Patients, comparing Zidovudine/Lamivudine vs Stavudine/Didanosine,
plus Efavirenz, Nevirapine or Indinavir/Ritonavir - 8/08/05
Salvage
Therapy in Different Clinical Settings - 8/05/05
Switching
from Stavudine to Tenofovir Decreases Cardiovascular Risk - 8/05/05
Switch
from PI- to Sustiva-based HAART Shows No Impact of Race on Efficacy
and Nervous System Symptoms - 8/03/05
TDF
Affects Renal Function but Renal Failure Is Rare - 8/03/05
Frequency
of Abacavir Hypersensitivity Reactions, Rechallenge Reactions, and
HSR-attributable Outcomes Are Similar with the Use of Ziagen or
Trizivir
-
8/01/05
Hyperbilirubinemia
among Patients in the HIV Outpatient Study (HOPS) Receiving Atazanavir
-
8/01/05
Tenofovir
Affects Renal Function but Renal Failure Is Rare
-
8/01/05
Safety
of a Fosamprenavir/Ritonavir-containing Regimen Over 120 Weeks in
HIV Positive Treatment-naïve Adults with or without hepatitis B
and/or C Coinfection
-
8/01/05
Safety
of Abacavir + Lamivudine-based HAART in ART-naïve HIV Positive Subjects
with and without Hepatitis B and/or Hepatitis C Coinfection
-
8/01/05
Pattern
of Hepatotoxicity on Different Antiretroviral Regimens in HIV Patients
with or without Chronic Hepatitis B or Hepatitis C
-
8/01/05
Liver
Disease and Not HCV Coinfection May Be Predictive of a Higher Discontinuation
of HAART
-
8/01/05
Mother-to-Child Transmission (MTCT) / Prevention
of MTCT / Pregnancy / Newborns
Routine
Use of Combined Zidovudine and Nevirapine Regimen in MTCT-Plus Program
- 8/03/05
Nevirapine
Concentration in Cervico-vaginal and Oropharyngeal Secretions
- 8/03/05
Timing
of Maternal and Infant Nevirapine and the Risk of Mother-to-child
Transmission of HIV - 8/03/05
6-month
Immunological Response with HAART-containing Nevirapine in HIV Positive
Women Post-exposure to Single-dose of Nevirapine for PMTCT - 8/03/05
Mother-to-Child
Transmission of HIV: Where We Are and Where We Need to Go
-
8/01/05
Drug
Resistance
Lack
of Resistance to Tenofovir at Week 48 and Impact of Baseline Resistance
Mutations on Treatment Response - 8/08/05
Antiviral
Activity and Safety of GW695634, a Next Generation NNRTI, in Patients
with NNRTI-resistant HIV -
8/08/05
HIV
Drug Resistance Acquired through Superinfection - 8/05/05
Incidence
of K65R Mutation Is Not Increasing - 8/05/05
Developing
Countries
Effective
Method for Transferring Skills and Knowledge to Developing Countries
- 8/05/05
Clinical
Mentoring Is Effective in Improving Skills for Health Care Providers
in Developing Countries - 8/05/05
Epidemiology
Contacts
of the New York City “Superinfection” Case Identified
-
9/09/05
Infection
with Resistant Virus Is Not Associated with More Rapid Disease Progression
-
9/09/05
Immunologic
Status at Time of Initial Evaluation: Consequences of Delayed HIV
Diagnoses
-
8/01/05
New Therapeutic Approaches
Treatment
with Recombinant Growth Hormone Increases Total and Naïve CD4 Count
Compared to HAART Alone -
7/27/05
Virological (Treatment) Failure
High
Rate of Virological Failure during Once-daily Therapy with Tenofovir
+ Didanosine 250mg + Efavirenz in Treatment-naive Patients - 8/08/05
Adverse
Events are the Main Cause of Treatment Failure in a Multicentre
Trial in Naïve Patients, comparing Zidovudine/Lamivudine vs Stavudine/Didanosine,
plus Efavirenz, Nevirapine or Indinavir/Ritonavir - 8/08/05
Quadruple
Nucleoside/tide Regimen of Trizivir + Tenofovir Is Effective Following
Early Virologic Failure on an Initial Regimen Containing a Thymidine
Analog + Lamivudine + a PI or NNRTI - 8/08/05
Vaccines
Vaccines
with Naked DNA Appear Effective in Reducing the Viral Setpoint
-
8/01/05
Treatment Strategies / Salvage Therapy
and Treatment Failure
Tipranavir/ritonavir
Demonstrates Superior Response to Lopinavir/ritonavir, Amprenavir/ritonavir
or Saquinavir/ritonavir in PI-experienced Patients - 8/08/05
Salvage
Therapy in Different Clinical Settings - 8/05/05
Tipranavir/ritonavir
500 mg/200 mg BID Drives Week 24 viral load <400 copies/mL When
Combined with Enfuvirtide in Protease Inhibitor-experienced HIV
Patients - 8/03/05
Once-Daily
Salvage Regimens for Heavily Treatment-experienced HIV-Infected
Patients in the Atazanavir Early Access Program in Spain - 8/03/05
Salvage
Study of Experimental HIV Protease Inhibitor TMC-114 from Tibotec
Yields Outstanding Results
-
8/01/05
Cost of HIV/AIDS Medical Care
Lifetime
Cost of HIV Care in the US in the Current Treatment Era
-
8/01/05
Pathogenesis
Host
Factors and Viral Interactions - 8/05/05
HIV
Pathogenesis - 7/29/05
Dosing / Once-Daily Dosing (QD) / Fixed-dose
Combinations
High
Rate of Virological Failure during Once-daily Therapy with Tenofovir
+ Didanosine 250mg + Efavirenz in Treatment-naive Patients - 8/08/05
Efficacy
and Safety of a Once-daily Fixed-dose Combination of Abacavir/Lamivudine
versus Abacavir Twice-daily and Lamivudine Once-daily as Separate
Entities in Treatment-experienced Patients -- 8/08/05
Patient
Satisfaction with Abacavir-Lamivudine Fixed-dose Combination (FDC)
Tablet Once daily (QD) Compared with Abacavirand Lamivudine Twice-daily
- 8/08/05
Once-daily
HAART More Effective than Twice-daily Regimen - 8/05/05
Efficacy
and Safety of Once-Daily Abacavir/Lamivudine Fixed-dose Combination
+ Efavirenz - 8/03/05
Once-Daily
Salvage Regimens for Heavily Treatment-experienced HIV-Infected
Patients in the Atazanavir Early Access Program in Spain - 8/03/05
Evaluation
of 3 Once-daily Regimens as First-line HAART
-
8/01/05
Outcome
of Once-daily Regimen with Didanosine, Lamivudine and Efavirenz
in Treatment-naïve Patients
-
8/01/05
Viral Diversity
Molecular
Epidemiology and Transmission - 8/03/05
Diversity
of HIV: Viral Recombinants Are Increasing - 8/03/05
Sexual Transmission of HIV
Molecular
Epidemiology and Transmission - 8/03/05
Update
on “Patient Zero” - 7/29/05
High Risk for Transmission of Drug-resistant
HIV among HIV Patients in Routine Clinical Care -
7/27/05
Patient Zero: the Connecticut Source of the Multi-drug Resistant,
Rapidly Progressing HIV-1 Strain Found in New York City -
7/27/05
|
